Basic Information
| RNALocate ID: | RLID:11002733 |
| RNA Symbol: | hsa-miR-423-3p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-423-3p |
| RNA ID: | miRBase:MIMAT0001340 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23077538 |
| Tissue/Cell Line: | Plasma |
| Method: | Solexa sequencing |
| Description: | To characterize the stability of secreted miRNAs in plasma, we selected eight plasma miRNAs with relatively high copy numbers detected by Solexa sequencing (Table S1).Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002262 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01002263 | Mitochondrion | Myotube | 27396686 |
| RLID:01002264 | Mitochondrion | Skeletal muscle cells | 27563705 |
| RLID:01002265 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002266 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01002267 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11002726 | Exosome | Human cervical carcinoma cell line (HeLa|SiHa) | 25760330 |
| RLID:11002727 | Exosome | Serum | 18589210 |
| RLID:11002728 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11002729 | Exosome | Brain tissue | 23382797 |
| RLID:11002730 | Exosome | Plasma | 23663360 |
| RLID:11002731 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11002732 | Microvesicle | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11002734 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000136 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
| RLID-D:11000447 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-423-3p | Splenic marginal zone lymphoma | MNDR-E-MI-48463 |
| MNDR | hsa-miR-423-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-48464 |
| MNDR | hsa-miR-423-3p | Lymphoma | MNDR-E-MI-48465 |
| MNDR | hsa-miR-423-3p | Lymphoma non-hodgkin | MNDR-E-MI-48466 |
| MNDR | hsa-miR-423-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-48467 |
| MNDR | hsa-miR-423-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-48468 |
| MNDR | hsa-miR-423-3p | Her2-receptor positive breast cancer | MNDR-E-MI-48469 |
| MNDR | hsa-miR-423-3p | Dermatomyositis | MNDR-E-MI-48470 |
| MNDR | hsa-miR-423-3p | Prostate cancer | MNDR-E-MI-48471 |
| MNDR | hsa-miR-423-3p | Gastric cancer | MNDR-E-MI-48472 |
| MNDR | hsa-miR-423-3p | Gastric lymphoma | MNDR-E-MI-48473 |
| MNDR | hsa-miR-423-3p | Alzheimer disease | MNDR-E-MI-48474 |
| MNDR | hsa-miR-423-3p | Intracranial aneurysm | MNDR-E-MI-48475 |
| MNDR | hsa-miR-423-3p | Urinary bladder cancer | MNDR-E-MI-48476 |
| MNDR | hsa-miR-423-3p | Polycystic ovary syndrome | MNDR-E-MI-48477 |
| MNDR | hsa-miR-423-3p | Muscular dystrophy duchenne | MNDR-E-MI-48478 |
| MNDR | hsa-miR-423-3p | Primary biliary cirrhosis | MNDR-E-MI-48479 |
| MNDR | hsa-miR-423-3p | Cardiovascular disease | MNDR-E-MI-48480 |
| MNDR | hsa-miR-423-3p | Lung cancer | MNDR-E-MI-48481 |
| MNDR | hsa-miR-423-3p | Parkinson disease | MNDR-E-MI-48482 |
| MNDR | hsa-miR-423-3p | Breast cancer | MNDR-E-MI-48483 |
| MNDR | hsa-miR-423-3p | Malignant mesothelioma | MNDR-E-MI-48484 |
| MNDR | hsa-miR-423-3p | Pancreatic cancer | MNDR-E-MI-48485 |
| MNDR | hsa-miR-423-3p | Melanoma | MNDR-E-MI-48486 |
| MNDR | hsa-miR-423-3p | Rectum adenocarcinoma | MNDR-E-MI-48487 |
| MNDR | hsa-miR-423-3p | Colon cancer | MNDR-E-MI-48488 |
| MNDR | hsa-miR-423-3p | Colon adenocarcinoma | MNDR-E-MI-48489 |
| MNDR | hsa-miR-423-3p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-48490 |
| MNDR | hsa-miR-423-3p | Familial ovarian cancer | MNDR-E-MI-48491 |
| MNDR | hsa-miR-423-3p | Prostate adenocarcinoma | MNDR-E-MI-48492 |
| MNDR | hsa-miR-423-3p | Laryngeal carcinoma | MNDR-E-MI-48493 |
| MNDR | hsa-miR-423-3p | Carcinoma ductal breast | MNDR-E-MI-48494 |
| MNDR | hsa-miR-423-3p | Glioblastoma | MNDR-E-MI-48495 |
| MNDR | hsa-miR-423-3p | Glioma | MNDR-E-MI-48496 |
| MNDR | hsa-miR-423-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-48497 |
| MNDR | hsa-miR-423-3p | Epilepsy temporal lobe | MNDR-E-MI-48498 |
| MNDR | hsa-miR-423-3p | Osteosarcoma | MNDR-E-MI-48499 |
| MNDR | hsa-miR-423-3p | Inclusion body myositis | MNDR-E-MI-48500 |
| MNDR | hsa-miR-423-3p | Middle cerebral artery infarction | MNDR-E-MI-48501 |
| MNDR | hsa-miR-423-3p | Gastric adenocarcinoma | MNDR-E-MI-48502 |
| MNDR | hsa-miR-423-3p | Lung squamous cell carcinoma | MNDR-E-MI-48503 |
| MNDR | hsa-miR-423-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-48504 |
| MNDR | hsa-miR-423-3p | Lung adenocarcinoma | MNDR-E-MI-48505 |
| MNDR | hsa-miR-423-3p | Thyroid carcinoma | MNDR-E-MI-48506 |
| MNDR | hsa-miR-423-3p | Bladder urothelial carcinoma | MNDR-E-MI-48507 |
| MNDR | hsa-miR-423-3p | Pancreatic adenocarcinoma | MNDR-E-MI-48508 |
| MNDR | hsa-miR-423-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-48509 |
| MNDR | hsa-miR-423-3p | Carcinoma renal cell | MNDR-E-MI-48510 |
| MNDR | hsa-miR-423-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-48511 |
| MNDR | hsa-miR-423-3p | Clear cell renal cell carcinoma | MNDR-E-MI-48512 |
| MNDR | hsa-miR-423-3p | Chromophobe renal cell carcinoma | MNDR-E-MI-48513 |
| MNDR | hsa-miR-423-3p | Cholangiocarcinoma | MNDR-E-MI-48514 |
| MNDR | hsa-miR-423-3p | Esophageal cancer | MNDR-E-MI-48515 |
| MNDR | hsa-miR-423-3p | Liver cirrhosis | MNDR-E-MI-48516 |
| MNDR | hsa-miR-423-3p | Oncocytoma | MNDR-E-MI-48517 |
| MNDR | hsa-miR-423-3p | Synovial sarcoma | MNDR-E-MI-48518 |
| MNDR | hsa-miR-423-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-48519 |
| MNDR | hsa-miR-423-3p | Fibromyalgia | MNDR-E-MI-48520 |
| MNDR | hsa-miR-423-3p | Encephalomyelitis | MNDR-E-MI-48521 |
| MNDR | hsa-miR-423-3p | Breast invasive carcinoma | MNDR-E-MI-48522 |
| MNDR | hsa-miR-423-3p | Hepatocellular carcinoma | MNDR-E-MI-48523 |
| MNDR | hsa-miR-423-3p | Familiar ovarian carcinoma | MNDR-E-MI-48524 |
| MNDR | hsa-miR-423-3p | B-cell lymphoma | MNDR-E-MI-48525 |
| MNDR | hsa-miR-423-3p | Rheumatoid arthritis | MNDR-E-MI-48526 |
| MNDR | hsa-miR-423-3p | T-cell leukemia | MNDR-E-MI-48527 |
| MNDR | hsa-miR-423-3p | Malignant pleural mesothelioma | MNDR-E-MI-48528 |
| MNDR | hsa-miR-423-3p | Barrett's adenocarcinoma | MNDR-E-MI-48529 |
| MNDR | hsa-miR-423-3p | Burkitt lymphoma | MNDR-E-MI-48530 |
| MNDR | hsa-miR-423-3p | Tonsil cancer | MNDR-E-MI-48531 |
| MNDR | hsa-miR-423-3p | Neuromyelitis optica | MNDR-E-MI-48532 |
| MNDR | hsa-miR-423-3p | Skin cutaneous melanoma | MNDR-E-MI-48533 |
| MNDR | hsa-miR-423-3p | Skin melanoma | MNDR-E-MI-48534 |
| MNDR | hsa-miR-423-3p | Colorectal cancer | MNDR-E-MI-48535 |
| MNDR | hsa-miR-423-3p | Epstein-barr virus infections | MNDR-E-MI-48536 |
| MNDR | hsa-miR-423-3p | Peripheral nerve injuries | MNDR-E-MI-48537 |
| MNDR | hsa-miR-423-3p | Chronic pain | MNDR-E-MI-48538 |
| MNDR | hsa-miR-423-3p | Stroke lacunar | MNDR-E-MI-48539 |
| MNDR | hsa-miR-423-3p | Barrett's carcinogenesis | MNDR-E-MI-48540 |
| MNDR | hsa-miR-423-3p | High grade dysplastic nodule | MNDR-E-MI-48541 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | BCL2L11 | Homo sapiens | RR00219397 |
TOP